FDA approves menin inhibitor for patients with acute leukemia with NPM1 mutation, backed by Dana-Farber science
November 04, 2025
November 04, 2025
BOSTON, Massachusetts, Nov. 4 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
FDA approves menin inhibitor for patients with acute leukemia with NPM1 mutation, backed by Dana-Farber science
*
The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloi . . .
* * *
FDA approves menin inhibitor for patients with acute leukemia with NPM1 mutation, backed by Dana-Farber science
*
The U.S. Food and Drug Administration (FDA) approved revumenib, a first-in-class oral menin inhibitor, for the treatment of adults and children one year and older with relapsed or refractory acute myeloi . . .